NSE: SUNPHARMA · 15 October 2026 · Pre-market update
- Sun Pharmaceutical Industries Limited is in focus ahead of the market open following credit rating updates from CRISIL and ICRA for its proposed non-convertible debenture programme and existing facilities. The rating actions factor in the company's strong business and financial profile alongside its proposed acquisition of Organon & Co.
- CRISIL and ICRA have assigned 'AAA/Stable' ratings to Sun Pharmaceutical Industries Limited's proposed non-convertible debenture (NCD) programme while reaffirming existing ratings on commercial paper, bank facilities, and short-term limits. The rating rationale highlights the company's strong domestic market leadership, robust specialty products portfolio, and the prospective financial impact of the proposed acquisition of Organon & Co.
- Trading volume was 1.13 times the 20-day average daily volume.
Sun Pharmaceutical Ind L Company News Before Market Open
Sun Pharmaceutical Industries Limited is in focus ahead of the market open following credit rating updates from CRISIL and ICRA for its proposed non-convertible debenture programme and existing facilities. The rating actions factor in the company's strong business and financial profile alongside its proposed acquisition of Organon & Co.
CRISIL and ICRA assigned 'AAA/Stable' ratings to the company's proposed non-convertible debenture programme. Existing long-term and short-term credit facilities alongside commercial paper programmes received rating reaffirmations. Evaluations factor in the company's resilient domestic formulation segment performance and ongoing preparation for the Organon & Co. acquisition.
18.09 lakh shares traded on 14 October 2026. This compares with a 20-day average daily volume of 15.98 lakh shares (1.13 times). The five-day average daily volume was 12.87 lakh shares.
CRISIL and ICRA assigned 'AAA/Stable' ratings to the company's proposed non-convertible debenture programme. Existing long-term and short-term credit facilities alongside commercial paper programmes received rating reaffirmations. Evaluations factor in the company's resilient domestic formulation segment performance and ongoing preparation for the Organon & Co. acquisition.
Latest Company Developments
CRISIL and ICRA have assigned 'AAA/Stable' ratings to Sun Pharmaceutical Industries Limited's proposed non-convertible debenture (NCD) programme while reaffirming existing ratings on commercial paper, bank facilities, and short-term limits. The rating rationale highlights the company's strong domestic market leadership, robust specialty products portfolio, and the prospective financial impact of the proposed acquisition of Organon & Co.
Maintains high credit standing for debt instruments while acknowledging the upcoming balance sheet transition and leverage changes associated with large-scale strategic acquisitions.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.84% on 30 June 2026. This compares with 11.96% on 31 March 2026, a change of +0.88 percentage points.
The filing reported 49 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Trading volume and price action relative to the prior session's close of Rs 1,746.40 and intraday range between Rs 1,725.50 and Rs 1,770.10.
- Investor sentiment regarding debt-funded acquisition plans and projected net leverage metrics post-Organon transaction.
- Execution progress and regulatory timelines concerning upcoming corporate integrations and specialty product rollouts.
Other Dated Coverage
- Sun Pharma in Focus After NCD Issuance Approval and Director Resignation | 14 October 2026 — 14 October 2026
- Sun Pharma in Focus After INR 10,000 Crore NCD Approval and Director Resignation | 13 October 2026 — 13 October 2026
- Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 1.28% | 7 October 2026 — 7 October 2026
More Sun Pharmaceutical Ind L news and dated analysis →
Frequently Asked Questions
What is the latest Sun Pharmaceutical Ind L company news?
CRISIL and ICRA have assigned 'AAA/Stable' ratings to Sun Pharmaceutical Industries Limited's proposed non-convertible debenture (NCD) programme while reaffirming existing ratings on commercial paper, bank facilities, and short-term limits. The rating rationale highlights the company's strong domestic market leadership, robust specialty products portfolio, and the prospective financial impact of the proposed acquisition of Organon & Co.
How strong was Sun Pharmaceutical Ind L’s trading volume?
18.09 lakh shares traded, 1.13 times the 20-day average daily volume. The price and volume data are dated 14 October 2026.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.